HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

1,126.267

-17.909-1.57%

Number of Gainers:2

Number of Losers:15

Number of Flat:1

PE:- -

High:1,140.894

Open:1,140.894

Low:1,114.037

Close:1,144.176

Volume:96.63M

Turnover:962.73M

Market Cap:760.87B

Float Cap:632.57B

Loading ...

Kintor Pharma-B Shares Surge Over 5% in Morning Session on Strategic Skincare Partnership

Sinopharm Accord net profit rises 76.8% to RMB1.14 billion in 2025

Sinopharm Group FY Revenue RMB 73,416 Million

THOMSON REUTERS

GPC and Baiyunshan Launch Phase One of Financial Transformation Initiative

Byd Company Secures Major 100,000-Vehicle Export Order Amid Intensifying EV Competition

BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026

Sino Biopharmaceutical Gets China Nod for Osteoarthritis Drug Trial

MT Newswires Live

Shanghai Chicmax Cosmetic signs strategic cooperation agreement with Suzhou Kintor for KT-939 commercialization

China Biopharma's Novel Drug TRD221 Receives NMPA Clearance for Clinical Trials

BRIEF-Sino Biopharmaceutical Says TRD221 Receives NMPA Clinical Trial Approval For Osteoarthritis Treatment

Sino Biopharmaceutical - Trd221 Receives Nmpa Clinical Trial Approval for Osteoarthritis Treatment

THOMSON REUTERS

Ascletis targets Q3 2026 FDA IND filing for ASC39 oral obesity tablets

ASCLETIS-B Selects Oral Amylin Receptor Agonist ASC39 as Clinical Candidate, Demonstrating Eloralintide-Like Selectivity and Efficacy in Preclinical Models

Ascletis Pharma Inc - Expects to Submit Ind Application to U.S. FDA for Asc39 Oral Tablets in Q3 2026

THOMSON REUTERS

Ascletis says ASC39 delivered 6.6% placebo-adjusted weight loss in obese rats and targets US FDA IND filing in Q3 2026

Sinopharm Group Stock Sheds 1.2% in Hong Kong

BYD Claims Top Spot in Hong Kong's 2025 Vehicle Sales, First Chinese Brand to Achieve This Feat

BYD Launches Spring Recruitment Drive Hiring Over 4,000 Workers with Monthly Salaries Up to 10,000 Yuan

CSPC Pharmaceutical Group Stock Rises 0.9% in Hong Kong

Baiyunshan Pharma's Subsidiary Gets Nod for Xu Han Ting Granules' Trial As Respiratory Treatment

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1515/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":1126.267,"timestamp":1774835675084,"preClose":1144.1763,"halted":0,"volume":96626572,"delay":0,"changeRate":-0.015653,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-17.909302,"latestTime":"03-30 09:54:35","open":1140.8938,"high":1140.8938,"low":1114.0369,"amount":962732971,"amplitude":0.023473,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1774843200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774834200000,1774843200000],[1774846800000,1774857600000]],"pbRate":2.080562,"peRate":22.562636,"turnoverRate":0.001321,"increases":2,"decrements":15,"flats":0,"marketCap":760870681984,"floatMarketCap":632574424832},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":1140.8938,"amplitude":0.023473,"preClose":1144.1763,"low":1114.0369,"pbRate":"2.080562","latestPrice":1126.267,"volume":96626572,"delay":0,"open":1140.8938,"prevYearClose":1190.107,"prevWeekClose":1144.176,"prevMonthClose":1247.044,"prevQuarterClose":1190.107,"fiveDayClose":1091.255,"twentyDayClose":1200.531,"sixtyDayClose":1205.635,"secType":"PLATE","market":"HK","turnoverRate":0.001321,"peRate":22.562636,"marketCap":760870681984,"floatMarketCap":632574424832,"timestamp":1774835675084,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":2,"down":15,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1134627223","title":"Kintor Pharma-B Shares Surge Over 5% in Morning Session on Strategic Skincare Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=1134627223","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134627223?lang=en_us&edition=fundamental","pubTime":"2026-03-18 09:40","pubTimestamp":1773798017,"startTime":"0","endTime":"0","summary":"Kintor Pharma-B (09939) saw its shares rise more than 5% during morning trading. At the time of writing, the stock was up 5.54%, trading at HK$4.38, with a turnover of HK$1.9909 million. The increase...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4585","02145","KT","SG9999004220.SGD","LU0541502299.USD","VXUS","BK4588","LU2242644610.SGD","LU0455707207.USD","BK1207","BK4115","BK1515","BK1161","09939","LU0541501648.USD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2620406403","title":"Sinopharm Accord net profit rises 76.8% to RMB1.14 billion in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2620406403","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620406403?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:14","pubTimestamp":1773785640,"startTime":"0","endTime":"0","summary":"Sinopharm said subsidiary Sinopharm Accord reported 2025 revenue of RMB73.42 billion, down 1.29%. Sinopharm Accord reported net profit attributable to shareholders of RMB1.14 billion, up 76.8%, and basic earnings per share of RMB2.04, up 77.39%. Operating profit rose to RMB1.51 billion, more than doubled from a year earlier. Sinopharm Accord’s retail unit Guoda Drugstore reported revenue of RMB20.98 billion, down 6.16%, and net profit of RMB-217 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 17, 2026, and is solely responsible for the information c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9ZswZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","LU1115378108.SGD","BK0185","BK0175","BK0010","BK1500","LU0640798160.USD","01099","000028","BK0188","BK0082","BK1197","BK1515","BK0028","BK0250"],"gpt_icon":0},{"id":"2620471406","title":"Sinopharm Group FY Revenue RMB 73,416 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471406?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:12","pubTimestamp":1773785561,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLXE6D20E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","LU0640798160.USD","LU1115378108.SGD","BK1197","BK1500","01099"],"gpt_icon":0},{"id":"1197030422","title":"GPC and Baiyunshan Launch Phase One of Financial Transformation Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=1197030422","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197030422?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:50","pubTimestamp":1773755450,"startTime":"0","endTime":"0","summary":"On March 13, Guangzhou Pharmaceutical Holdings Limited (GPC) and Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited jointly held a kick-off meeting for the first phase of their financial...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600332","00874","BK0012","BK0070","BK0196","BK1521","BK0183","BK0239","BK0028","BK0097","BK1191","BK1197","BK0175","BK0096","BK1606","BK1515","BK0188"],"gpt_icon":0},{"id":"1187357954","title":"Byd Company Secures Major 100,000-Vehicle Export Order Amid Intensifying EV Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=1187357954","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187357954?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:15","pubTimestamp":1773753322,"startTime":"0","endTime":"0","summary":"Byd Company Limited has secured an export order for 100,000 vehicles from its newly operational factory in Brazil. The shipment will be split evenly, with 50,000 vehicles destined for Argentina and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1251922891.USD","BK0188","SG9999015986.USD","LU2348774022.SGD","BK0072","LU0164865239.USD","LU0634319403.HKD","BK1580","LU0244354667.USD","LU0289961442.SGD","LU0856984785.SGD","LU1720050803.USD","LU0469268626.HKD","BK0070","LU0463099449.HKD","LU0269904917.USD","SG9999014674.SGD","LU0054450605.USD","01211","002594","81211","LU0509642566.USD","LU0540923850.HKD","LU0588545730.USD","BK1607","BK0014","LU2476274720.SGD","LU0143863198.USD","LU2097828474.EUR","LU0828238088.HKD","LU0289739343.SGD","BK1504","LU1580142542.USD","BK1610","LU0683595622.HKD","IE00BD6J9T35.USD","LU0633140560.USD","LU1997245094.SGD","LU0348825331.USD","LU2097828557.USD","LU0254981946.USD","LU0164872284.USD","LU2097828805.USD","LU0823414551.USD","LU1188198961.HKD","LU1997245177.USD","LU1303224171.USD","LU0516422366.SGD","LU0320764599.SGD","LU0326950275.SGD","LU0327786744.USD","BK1582","LU0505663152.USD","LU1868837565.USD","SG9999015978.USD","LU0348827113.USD","LU0084288322.USD","LU0516422952.EUR","LU0594300419.USD","SG9999002463.SGD","LU0588545904.SGD","LU1064130708.USD","LU2039709279.SGD","LU2663582299.SGD","LU0819123356.HKD","LU1868837722.USD","LU1719994722.HKD","LU0274383008.USD","LU0143863784.USD","LU0823039010.USD","LU0572944931.SGD","SG9999001226.SGD","LU0315178854.USD","LU2580892789.USD","LU2148510915.USD","LU0871576103.HKD","LU1146622755.USD","LU2153592121.USD","LU1770034418.SGD","LU0449515922.USD","HYDD.SI","LU0594300179.USD","LU1861219969.SGD","LU0588546209.SGD","LU2294711713.HKD","LU2449936058.SGD","LU2506951792.HKD","RIVN","LU0417516738.SGD","SG9999015952.SGD","LU2778985437.USD","BK1149","LU0175139822.USD","BK1119","BK1539","BK1509","BK0183","SG9999015945.SGD","LU2357125470.USD","SG9999006514.SGD","LU1023057109.AUD","LU0633140727.USD","LU1064131003.USD","LU0348735423.USD","BK1522","LU1861214812.USD","LU1328277881.USD","LU1880383366.USD","LU0348766576.USD","LU0043850808.USD","LU0417516902.SGD","LU0516422440.USD","SG9999006597.SGD","LU0865486749.SGD","LU0823426308.USD","LU2495084118.USD","LU2328871848.SGD","LU0348805143.USD","LU0214875030.USD","LU2360107325.USD","LU2399975544.HKD","LU0211977185.USD","LU0516423174.USD","LU0307460666.USD","LU0359202008.SGD","LU1808992512.USD","LU2097828714.EUR","LU0819121731.USD","LU1794554557.SGD","LU0039217434.USD","LU0823426480.USD","SG9999002828.SGD","BK1515","LU0229945570.USD","LU1969619763.USD","LU1242518857.USD","LU1242518931.SGD","LU2249611893.SGD","LU0259732245.USD","LU2580892862.HKD","LU0605514214.HKD","BYDDY","LU0823038988.USD","LU0650527681.SGD","LU0979878070.USD","BK0264","EVS.SI","LU0708995583.HKD","LU1868838027.USD","LU0516423091.SGD","LU1820825898.SGD","BK1594","LU0593848301.USD","LU0052750758.USD","LU0561508036.HKD","LU0511384066.AUD","LU0823414478.USD","LU0348767384.USD","BK0196","LU0588545490.SGD","LU0359201612.USD","LU1880383440.USD","LU0531971595.HKD","LU1997244956.HKD","LU1813983027.USD","LU1508157978.USD","LU1961090484.USD","LU2097828631.EUR","LU0359201885.HKD","LU2476274308.USD","BK1589","BK0155","LU0449509016.USD","LU1781817850.SGD","LU0165289439.USD","BK1540","LU0531970944.HKD","LU0314109678.HKD","BK0169","LU0289960550.SGD","LU0543330566.HKD","LU2289578879.USD"],"gpt_icon":1},{"id":"2620601422","title":"BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620601422","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620601422?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:40","pubTimestamp":1773751215,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026March 17 (Reuters) - Ascletis Pharma Inc 1672.HK:EXPECTS TO SUBMIT IND APPLICATION TO U.S. FDA FOR ASC39 ORAL TABLETS IN Q3 2026Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN404121:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK1574","BK1161"],"gpt_icon":0},{"id":"2620243524","title":"Sino Biopharmaceutical Gets China Nod for Osteoarthritis Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2620243524","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620243524?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:06","pubTimestamp":1773749204,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical (HKG:1177) obtained clinical trial approval for TRD221, developed by unit Beijing Tide Pharmaceutical, from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug is intended for the treatment of osteoarthritis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1589","BK1191","HK0000165453.HKD","BK1521","BK1515","IE00BZ08YT58.USD","01177"],"gpt_icon":0},{"id":"2620342171","title":"Shanghai Chicmax Cosmetic signs strategic cooperation agreement with Suzhou Kintor for KT-939 commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2620342171","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620342171?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:01","pubTimestamp":1773748917,"startTime":"0","endTime":"0","summary":"Shanghai Chicmax Cosmetic said it entered a strategic cooperation framework agreement with Suzhou Kintor, a unit of Kintor Pharmaceutical, covering the cosmetics field under an exclusivity clause. The parties will work on registering KT-939 as a new cosmetic ingredient in China and on registering cosmetic products that use KT-939 as a core ingredient. They also plan joint R&D and customization work related to KT-939, which is described as a whitening and freckle-removing ingredient.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Chicmax Cosmetic Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 17, 2026, and is s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLc3tSwr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1574","LU2242644610.SGD","LU0455707207.USD","02145","BK1207","LU0502904849.HKD","BK1515","BK1161"],"gpt_icon":0},{"id":"1133693442","title":"China Biopharma's Novel Drug TRD221 Receives NMPA Clearance for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1133693442","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133693442?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:18","pubTimestamp":1773742704,"startTime":"0","endTime":"0","summary":"SINO BIOPHARM (01177) announced that its subsidiary, Beijing Tide Pharmaceutical Co., Ltd., has obtained clinical trial approval from the National Medical Products Administration (NMPA) for TRD221, a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1589","BK1191","HK0000165453.HKD","BK1521","BK1515","IE00BZ08YT58.USD","01177"],"gpt_icon":0},{"id":"2620632423","title":"BRIEF-Sino Biopharmaceutical Says TRD221 Receives NMPA Clinical Trial Approval For Osteoarthritis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2620632423","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620632423?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:13","pubTimestamp":1773742405,"startTime":"0","endTime":"0","summary":"BRIEF-Sino Biopharmaceutical Says TRD221 Receives NMPA Clinical Trial Approval For Osteoarthritis TreatmentMarch 17  - Sino Biopharmaceutical Ltd 1177.HK:TRD221 RECEIVES NMPA CLINICAL TRIAL APPROVAL FOR OSTEOARTHRITIS TREATMENTFurther company coverage: 1177.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN40508Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1521","IE00BZ08YT58.USD","01177","BK1515","BK1191","BK1589","HK0000165453.HKD"],"gpt_icon":0},{"id":"2620236884","title":"Sino Biopharmaceutical - Trd221 Receives Nmpa Clinical Trial Approval for Osteoarthritis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2620236884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620236884?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:12","pubTimestamp":1773742334,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN40508Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","01177","BK1589","BK1191","BK1521","IE00BZ08YR35.GBP","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2620428779","title":"Ascletis targets Q3 2026 FDA IND filing for ASC39 oral obesity tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620428779?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:01","pubTimestamp":1773741708,"startTime":"0","endTime":"0","summary":"Ascletis selected ASC39, an oral small-molecule amylin receptor agonist, as a clinical development candidate for obesity and said it expects to submit a U.S. FDA IND for ASC39 tablets in Q3 2026. Preclinical results were presented in the announcement, including a head-to-head cAMP assay in which ASC39 had an EC50 of 21.4 pM at hAMY1R and 846.1 pM at hCTR. In a diet-induced obese rat study, once-daily oral ASC39  produced 6.6% placebo-adjusted weight loss over 6 days. In the same study, eloralintide produced 5.6% placebo-adjusted weight loss with once-every-three-day subcutaneous dosing  over 6 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLXrsqL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK1574","01672"],"gpt_icon":0},{"id":"1190050395","title":"ASCLETIS-B Selects Oral Amylin Receptor Agonist ASC39 as Clinical Candidate, Demonstrating Eloralintide-Like Selectivity and Efficacy in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=1190050395","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190050395?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:52","pubTimestamp":1773741162,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) has announced its board of directors' decision to select ASC39, a potent and selective oral small molecule amylin receptor agonist, as a candidate for clinical development. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1191","BK1515","BK1161","01672"],"gpt_icon":0},{"id":"2620289884","title":"Ascletis Pharma Inc - Expects to Submit Ind Application to U.S. FDA for Asc39 Oral Tablets in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620289884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620289884?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:46","pubTimestamp":1773740800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN404121:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1574","BK1161","01672"],"gpt_icon":0},{"id":"2620646428","title":"Ascletis says ASC39 delivered 6.6% placebo-adjusted weight loss in obese rats and targets US FDA IND filing in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620646428","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620646428?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:45","pubTimestamp":1773740751,"startTime":"0","endTime":"0","summary":"Ascletis said oral small-molecule amylin receptor agonist candidate ASC39 showed an EC50 of 21.4 pM for the human amylin 1 receptor, versus 21.2 pM for eloralintide. In the same assay, ASC39 had an EC50 of 846.1 pM for the human calcitonin receptor, compared with 1,350.8 pM for eloralintide. In a diet-induced obese rat study, ASC39 achieved 6.6% placebo-adjusted weight loss after once-daily oral dosing for six days, versus 5.6% for eloralintide. Vehicle-treated obese rats showed a 0.6% total body weight change from baseline over the same period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLTDP31:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","BK1574","01672"],"gpt_icon":0},{"id":"2620442784","title":"Sinopharm Group  Stock Sheds 1.2% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620442784?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:46","pubTimestamp":1773737160,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slipped 1.2% to 21.18 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.1% to 25868.54.The stock's fall snapped a three-day winning streak.Sinopharm Group Co. Ltd. closed 5.2% short of its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 0.4%.Trading volume totaled 5.1 million shares, compared to the 50-day average of 5.5 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099","BK4175","BK1515","BK1500","LU0640798160.USD","SHTDY","LU1115378108.SGD","BK1197"],"gpt_icon":0},{"id":"1154932940","title":"BYD Claims Top Spot in Hong Kong's 2025 Vehicle Sales, First Chinese Brand to Achieve This Feat","url":"https://stock-news.laohu8.com/highlight/detail?id=1154932940","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154932940?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:42","pubTimestamp":1773736967,"startTime":"0","endTime":"0","summary":"Throughout 2025, BYD Company Limited achieved a historic performance in the Hong Kong automotive market, demonstrating strong leadership with an impressive total of 9,751 vehicles sold. This secured...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1580","LU2153592121.USD","BK0014","SG9999006597.SGD","LU0823414551.USD","SG9999015986.USD","LU0269904917.USD","LU0516423091.SGD","EVS.SI","LU0871576103.HKD","BK1589","LU0516422366.SGD","LU0588545490.SGD","LU0417516902.SGD","LU1720050803.USD","LU0979878070.USD","LU2289578879.USD","LU0326950275.SGD","LU0511384066.AUD","LU0307460666.USD","LU2580892789.USD","SG9999015952.SGD","HYDD.SI","01211","LU0164865239.USD","LU0315178854.USD","LU1861219969.SGD","LU0348766576.USD","LU1781817850.SGD","LU1997245094.SGD","LU0348825331.USD","LU0274383008.USD","LU0543330566.HKD","LU1880383366.USD","LU0594300419.USD","LU2399975544.HKD","LU0054450605.USD","LU2097828805.USD","LU0449515922.USD","BK0155","LU1146622755.USD","BK1539","LU0327786744.USD","BK1540","LU0039217434.USD","BK0169","LU0540923850.HKD","LU1861214812.USD","LU0348827113.USD","LU2039709279.SGD","LU2506951792.HKD","SG9999006514.SGD","LU0823038988.USD","LU1188198961.HKD","SG9999015978.USD","LU0259732245.USD","LU1997245177.USD","LU0561508036.HKD","LU0254981946.USD","LU0819121731.USD","LU2580892862.HKD","LU0828238088.HKD","LU0819123356.HKD","LU1719994722.HKD","LU2357125470.USD","LU0865486749.SGD","LU0823426308.USD","LU2476274720.SGD","LU1580142542.USD","LU1770034418.SGD","LU2097828631.EUR","BK0072","LU0463099449.HKD","LU0244354667.USD","LU2097828557.USD","LU0516422440.USD","LU2778985437.USD","BK1119","002594","BK0188","LU2348774022.SGD","LU0348767384.USD","LU1808992512.USD","LU0505663152.USD","LU0856984785.SGD","LU0359201885.HKD","LU0572944931.SGD","SG9999002463.SGD","LU1868838027.USD","LU0289739343.SGD","LU2097828714.EUR","LU0143863784.USD","LU0634319403.HKD","LU0043850808.USD","LU2495084118.USD","BK1522","LU1820825898.SGD","SG9999002828.SGD","LU0211977185.USD","LU0143863198.USD","LU0588545904.SGD","LU1251922891.USD","BK1582","LU0229945570.USD","LU1961090484.USD","LU2663582299.SGD","LU1880383440.USD","LU0516423174.USD","BK1594","LU0289961442.SGD","LU0359202008.SGD","LU2476274308.USD","LU0594300179.USD","LU0320764599.SGD","LU1969619763.USD","LU0650527681.SGD","LU2449936058.SGD","BK1509","LU0531971595.HKD","BK1504","SG9999014674.SGD","81211","BK0070","LU0469268626.HKD","BK0196","LU0165289439.USD","LU0633140727.USD","LU2249611893.SGD","LU0588546209.SGD","LU1328277881.USD","BK1149","LU0516422952.EUR","LU1794554557.SGD","LU0823039010.USD","BK1607","LU0214875030.USD","LU0708995583.HKD","LU1868837565.USD","LU0175139822.USD","SG9999015945.SGD","BK0264","BK1515","LU2148510915.USD","LU0531970944.HKD","LU0588545730.USD","BK0183","LU0605514214.HKD","IE00BD6J9T35.USD","LU1303224171.USD","LU0314109678.HKD","LU1242518857.USD","LU2097828474.EUR","LU1508157978.USD","LU2328871848.SGD","LU1997244956.HKD","LU2294711713.HKD","LU0348805143.USD","LU2360107325.USD","BYDDY","BK1610","SG9999001226.SGD","LU0509642566.USD","LU1868837722.USD","LU0289960550.SGD","LU0593848301.USD","LU0359201612.USD","LU0164872284.USD","LU0449509016.USD","LU1064131003.USD","LU0823414478.USD","LU1813983027.USD","LU0823426480.USD","LU0348735423.USD","LU1023057109.AUD","LU0417516738.SGD","LU0633140560.USD","LU1242518931.SGD","LU0052750758.USD","LU0084288322.USD","LU0683595622.HKD","LU1064130708.USD"],"gpt_icon":1},{"id":"1179067479","title":"BYD Launches Spring Recruitment Drive Hiring Over 4,000 Workers with Monthly Salaries Up to 10,000 Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1179067479","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179067479?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:42","pubTimestamp":1773736930,"startTime":"0","endTime":"0","summary":"BYD has initiated a large-scale spring recruitment campaign across multiple production bases in China, aiming to hire more than 4,000 industrial workers. On March 12, the company's Shenzhen-Shanwei...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","002594","LU2153592121.USD","BK1594","BK0183","LU1997244956.HKD","LU1328277881.USD","LU1770034418.SGD","LU0509642566.USD","LU0359201885.HKD","LU0143863198.USD","LU0593848301.USD","LU1303224171.USD","LU2294711713.HKD","LU1580142542.USD","EVS.SI","LU0348827113.USD","LU0289961442.SGD","LU0307460666.USD","LU0327786744.USD","LU1808992512.USD","SG9999006597.SGD","LU0359201612.USD","BK0188","BK0196","SG9999015952.SGD","LU0039217434.USD","LU2097828474.EUR","LU0823038988.USD","LU1861219969.SGD","LU0531971595.HKD","LU2148510915.USD","BK1509","LU0511384066.AUD","LU0823414551.USD","SG9999015986.USD","BK0072","LU0633140560.USD","LU0289739343.SGD","LU2357125470.USD","LU0823426308.USD","LU0348805143.USD","LU1997245094.SGD","LU2249611893.SGD","BK1580","BK1522","LU0819123356.HKD","BK1149","LU2097828631.EUR","LU2348774022.SGD","LU0043850808.USD","LU0531970944.HKD","HYDD.SI","LU0588546209.SGD","LU0823039010.USD","LU0594300179.USD","BK0070","LU0650527681.SGD","LU0979878070.USD","LU2328871848.SGD","LU0164872284.USD","LU2506951792.HKD","LU1813983027.USD","LU0211977185.USD","SG9999002463.SGD","LU0516422366.SGD","LU0871576103.HKD","LU0214875030.USD","LU0505663152.USD","LU1064130708.USD","LU1868837722.USD","LU2360107325.USD","LU1146622755.USD","LU2476274720.SGD","LU0516422440.USD","LU1508157978.USD","LU1880383366.USD","LU0348767384.USD","LU0463099449.HKD","LU0417516902.SGD","LU1794554557.SGD","LU1880383440.USD","LU2449936058.SGD","LU1064131003.USD","LU0052750758.USD","LU0469268626.HKD","LU0588545904.SGD","LU0348735423.USD","LU0819121731.USD","BYDDY","LU1251922891.USD","LU0449515922.USD","LU0314109678.HKD","SG9999002828.SGD","LU1242518931.SGD","LU1719994722.HKD","LU0708995583.HKD","LU0594300419.USD","BK0014","LU2039709279.SGD","81211","BK0169","LU1242518857.USD","LU0516423174.USD","LU0634319403.HKD","LU0588545490.SGD","IE00BD6J9T35.USD","LU2663582299.SGD","LU0605514214.HKD","LU2580892789.USD","LU1720050803.USD","LU1023057109.AUD","LU2399975544.HKD","LU1997245177.USD","LU2289578879.USD","01211","LU0259732245.USD","LU0229945570.USD","BK1607","LU0359202008.SGD","SG9999015945.SGD","LU1868837565.USD","LU1868838027.USD","LU0348766576.USD","LU0254981946.USD","LU0543330566.HKD","SG9999015978.USD","LU0165289439.USD","BK1504","LU0274383008.USD","LU0588545730.USD","LU0856984785.SGD","LU2778985437.USD","LU0417516738.SGD","LU0348825331.USD","LU0315178854.USD","LU2476274308.USD","BK1540","LU0823414478.USD","LU1861214812.USD","LU2580892862.HKD","LU0175139822.USD","LU1961090484.USD","LU0289960550.SGD","LU0054450605.USD","LU2495084118.USD","LU0633140727.USD","LU0143863784.USD","LU0449509016.USD","LU1969619763.USD","LU0540923850.HKD","LU0164865239.USD","LU0516422952.EUR","LU0084288322.USD","LU2097828714.EUR","LU0828238088.HKD","LU0269904917.USD","LU0320764599.SGD","LU0823426480.USD","LU1188198961.HKD","BK1119","BK1582","LU2097828557.USD","LU0683595622.HKD","BK1589","BK1610","LU0326950275.SGD","SG9999006514.SGD","LU0244354667.USD","LU0516423091.SGD","LU1820825898.SGD","LU1781817850.SGD","BK1539","BK0264","LU0865486749.SGD","LU0572944931.SGD","SG9999001226.SGD","BK0155","LU0561508036.HKD","SG9999014674.SGD","LU2097828805.USD"],"gpt_icon":1},{"id":"2620442654","title":"CSPC Pharmaceutical Group Stock Rises 0.9% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442654","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620442654?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:33","pubTimestamp":1773736380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. inched 0.9% higher to 9.11 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.1% to 25868.54.This was the stock's second consecutive day of gains.CSPC Pharmaceutical Group Ltd. closed 22% below its 52-week high of HK$11.63, which the company reached Sept. 9.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. fell 0.7%, SSY Group Ltd. rose 1.6%, and United Laboratories International Holdings Ltd. fell 1.8%.Trading volume totaled 81.0 million shares, compared to the 50-day average of 113.1 million shares.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008368742.USD","BK1191","LU1226288170.HKD","LU0072913022.USD","LU1226287529.USD","LU1226287792.SGD","LU0880133367.SGD","LU0315179316.USD","IE0008369823.USD","LU1993786604.SGD","LU1152091754.HKD","LU1152091168.USD","LU1807302812.USD","IE00BZ08YR35.GBP","SG9999004220.SGD","BK1521","IE00B031HY20.USD","LU1328277881.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1515","LU0140636845.USD","LU1008478684.HKD","LU0067412154.USD","IE00BZ08YT58.USD","LU1960683339.HKD","IE00B5MMRT66.SGD","LU2039709279.SGD","LU0314109678.HKD","LU1951186391.HKD","LU0326950275.SGD","IE00B543WZ88.USD","LU0501845795.SGD","LU1226287875.USD","LU1226288253.USD","LU1813983027.USD","01093"],"gpt_icon":0},{"id":"2620841258","title":"Baiyunshan Pharma's Subsidiary Gets Nod for Xu Han Ting Granules' Trial As Respiratory Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2620841258","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620841258?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:21","pubTimestamp":1773717676,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical's  subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trial of Xu Han Ting Granules for a new indication, according to a Shanghai bourse filing on Tuesday.The drug will be tested as a treatment for recurrent respiratory tract infections in children.The pharmaceutical company's Hong Kong shares rose 2% during the morning trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1521","BK0175","BK1515","BK1197","BK0097","BK0183","BK1191","BK1606","BK0239","BK0096","BK0012","600332","BK0028","BK0070","BK0188","BK0196","00874"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":11,"totalSize":249,"code":"91000000","status":"200"}]}}